News
Medpage Today on MSN1mon
First Generics for Low-Dose Rivaroxaban Get FDA Approvaland to reduce the risk of major thrombotic vascular events in adults with peripheral artery disease (PAD), including patients ...
CLICK TO TWEET: Late-breaking data at #ACC21 offer insights on long-term prevention of future thrombotic events in patients with #PAD after lower-extremity revascularization. Full @JanssenUS press ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback